Appendix

Appendix Table S1. Percentage of animals with exophers.	2
Appendix Table S2. List of all C. elegans strains used in this study.	4
Appendix Table S3. List of all oligonucleotides strains used in this study.	.5

Figure	Condition	Percentage of
number		animals with
		exophers
Figure 1F	Control	100%
Figure 1H	Control	97%
	atg-7 RNAi	89%
	<i>lgg-1</i> RNAi	95%
Figure 1I	Control	93%
	<i>hsf-1</i> RNAi	93%
Figure 1J	Oxidative stress +	97%
	Oxidative stress -	100%
	Heat stress +	97%
	Heat stress -	90%
Figure 2A	Hermaphrodite day 0	0%
	Hermaphrodite day 1	69%
	Hermaphrodite day 2	98%
	Hermaphrodite day 3	92%
	Hermaphrodite day 4	84%
	Hermaphrodite day 5	79%
	Hermaphrodite day 6	78%
	Hermaphrodite day 7	72%
	Hermaphrodite day 8	73%
	Hermaphrodite day 9	74%
	Hermaphrodite day 10	84%
	Hermaphrodite day 11	78%
	Hermaphrodite day 12	82%
	Hermaphrodite day 13	93%
	Hermaphrodite day 14	86%
	Hermaphrodite day 15	88%
	Male day 0	0%
	Male day 1	1%
	Male day 2	5%
	Male day 3	7%
	Male day 4	33%
	Male day 5	31%
	Male day 6	32%
	Male day 7	35%
	Male day 8	36%
	Male day 9	58%
	Male day 10	64%
	Male day 11	55%
	Male day 12	62%
	Male day 13	54%
	Male day 14	58%
	Male day 15	70%

Appendix Table S1. Percentage of animals with exophers.

Figure 2B	15°C without offspring	40%
	15°C with offspring	79%
	25°C without offspring	42%
	25°C with offspring	100%
Figure 2D	Control	95%
	FUdR	15%
Figure 3A	Control	89%
Figure 3B	Control	93%
	goa-1 RNAi	87%
	egl-1 RNAi	98%
	egl-4 RNAi	98%
Figure 3C	Control L4 \rightarrow AD1	26%
	Starved L4 \rightarrow AD1	16%
	Control AD2 \rightarrow AD3	80%
	Starved AD2 \rightarrow AD3	98%
Figure 3E	Control	94%
	Embryo-conditioned buffer	95%
Figure 3F	Control	96%
	emb-27 RNAi	93%
Figure 4E	Control	90%
	<i>vit-2</i> RNAi	100%
Figure 4G	Control	98%
	rme-2 RNAi	34%
Figure S1B	Control	96%
	emb-8 RNAi	93%
	<i>pod-1</i> RNAi	89%
Figure S2A	Control (H)	95%
	Embryos lysate (H)	100%
	Larvae lysate (H)	100%
	Control (M)	9%
	Embryos lysate (M)	6%
Figure S2B	Control	97%
	<i>egl-1</i> RNAi	98%
	Control + FUdR	33%
	<i>egl-1</i> RNAi + FUdR	29%
Figure S2D	Control	100%
	unc-45 RNAi	71%
	Control	93%
	unc-54 RNAi	98%
Figure S4A	Control	96%
	<i>ced-1</i> RNAi	99%
	<i>ced-6</i> RNAi	96%

Strain	Genotype	Usage	Reference
N2	Wild type	Figure 3E	Brenner 1974
ACH91	wacIs6[myo-3p::pas-7::GGGGS Linker-	Figure 1A, J;	Generated for
	wrmScarlet::unc-54 3'UTR, unc-	Figure 4E	this study
	119(+)], wacIs14[myo-3p::tomm-20_1-	Figure S2D	
	50aa::attB5::mGFP::unc-54-3'UTR,		
	unc-119(+)]		
ACH93	wacIs1[myo-3 promoter::rpn-5	Figure 1A-B, E-I;	Generated for
	CAI=0.97::GGGGS Linker-	Figure 2A, D-E;	this study
	wrmScarlet::unc-54 3'UTR, unc-	Figure 3A-C, E-	
	119(+)], wacIs14[myo-3	F; Figure 4B-D,	
	promoter::tomm-20_1-	G, I; Figure S1A-	
	50aa::attB5::mGFP::unc-54-3'UTR,	B;	
	unc-119(+)]	Figure S2A-C	
		Figure S3	
		Figure S4A	
ACH199	wacIs1[myo-3 promoter::rpn-5	Figure 1C,	Generated for
	CAI=0.97::GGGGS Linker-	Figure 4F,H;	this study
	wrmScarlet::unc-54 3'UTR, unc-	Figure S1C-D	
	119(+)], vit-2(crg9070[vit-2::gfp]) X	Figure S4B-C	
AGD885	<i>rrf-3(b26) II; fem-1(hc17) IV; uthEx633</i>	Figure 2B-C	Vilchez et al.
	[myo-3p::GFP]		2012
TUR5	wacIs1[myo-3 promoter::rpn-5	Figure 1D	Generated for
	CAI=0.97::GGGGS Linker-		this study
	wrmScarlet::unc-54 3'UTR, unc-		
	119(+)], wacIs14[myo-3		
	promoter::tomm-20_1-		
	50aa::attB5::mGFP::unc-54-3'UTR,		
	unc-119(+)], wwaEx2[unc-122		
	promoter::GFP]		
CB4088	him-5(e1490)V	Figure 2B	Caenorhabditis
			Genetics Centre

Appendix Table S2. List of all C. elegans strains used in this study.

OLIGONUCLEOTIDE	SOURCE	IDENTIFIER
MT38_pCG150trimmed_Fwd_3UTRunc-54	Sigma-Aldrich	N/A
5'-AACTGTTTATAATTCACTGGCCGTCGTTTTAC-3'	-	
MT47_3UTRunc-54_Rev_pCG150trimmed	Sigma-Aldrich	N/A
5'-TGAATTATAAACAGTTATGTTTGGTATATTGG-3'		
MT39_pCG150trimmed_Rev_myo-3prom	Sigma-Aldrich	N/A
5'-TAATCACTATAGCTTGGCGTAATCATGGTCAT-3'		
MT40_myo-3prom_Fwd_pCG150trimmed	Sigma-Aldrich	N/A
5'-CAAGCTATAGTGATTATAGTCTCTGTTTTCGT-3'		
MT62_tomm-20_Fwd_myo-3prom	Sigma-Aldrich	N/A
5'-atccatctagaaGTTaaaaATGTCAGATACCATTCTCGGA-3'		
MT63_tomm-20_Rev_GFP	Sigma-Aldrich	N/A
5'-CCCTTGGATTCAACTTTTGTATACAAAGTTGTGGC-3'		
MT64_GFP_fwd_tomm-20	Sigma-Aldrich	N/A
5'-AAGTTGAATCCAAGGGAGAGGAGCTC-3'		
MT65_GFP_Rev_unc-54-3UTR	Sigma-Aldrich	N/A
5'-gagtaattggacGTTTTACTTGTAGAGCTCGTCCATTC-3'		
MT66 rpn-5 Fwd myo-3	Sigma-Aldrich	N/A
5'-atccatctagaaGTTaaaaATGGCAGACAGACGC-3'		
MT76_rpn-5_rev_OL-wrmScarlet	Sigma-Aldrich	N/A
5'-GGATCCACCACCTCCGGCACGTGGGGCG-3'		
MT74_OL-wrmScarlet_fwd 5'-	Sigma-Aldrich	N/A
GGAGGTGGTGGATCCGGAGGTGGTGGATCCGGAGGAGGAGGATC		
Cgtcagcaagggagaggc-3'		
MT69 wrmScarlet Rev unc-54	Sigma-Aldrich	N/A
5'-gagtaattggacGTTTTACTTGTAGAGCTCGTCCATTC-3'		
MT72_pas-7_fwd_myo-3_prom	Sigma-Aldrich	N/A
5'-atccatctagaaGTTatgagttcaatcggtaccgg-3'		
MT73_pas-7_rev_OL-wrmScarlet	Sigma-Aldrich	N/A
5'-GGATCCACCACCTCCttcaacttttgtatacaaagttgtatcgtc-3'		

Appendix Table S3. List of all oligonucleotides strains used in this study.